Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Takagi

Showing results (191-200 of 211) with videos related to

Pageof 22
Sort By:
Oncogene|December 11, 2024
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcomaSatoshi Takagi, Mikako Nakajima, Sumie Koike, et al.
Scientific Reports|August 23, 2017
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcomaNaoya Maekawa, Satoru Konnai, Satoshi Takagi, et al.
Scientific Reports|June 6, 2022
Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapyNaoya Maekawa, Satoru Konnai, Yumie Asano, et al.
American Journal of Hematology|May 6, 2017
A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformationAntonio Sacco, Yawara Kawano, Michele Moschetta, et al.
Internal Medicine (Tokyo, Japan)|November 20, 2018
Community-acquired Disseminated Exophiala dermatitidis Mycosis with Necrotizing Fasciitis in Chronic Graft-versus-host DiseaseEiichi Sato, Atsushi Togawa, Michio Masaki, et al.
The Journal of Cell Biology|November 5, 2003
Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalitiesSatoru Yamazaki, Ryo Iwamoto, Kazuko Saeki, et al.
Cancers|June 10, 2023
Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant MelanomaTatsuya Deguchi, Naoya Maekawa, Satoru Konnai, et al.
NPJ Precision Oncology|February 13, 2021
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanomaNaoya Maekawa, Satoru Konnai, Maki Nishimura, et al.
JCI Insight|December 7, 2021
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylationRay Sagawa, Seiji Sakata, Bo Gong, et al.
Plos One|January 26, 2023
Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumorsNaoya Maekawa, Satoru Konnai, Yumie Asano, et al.
Pageof 22

Showing results (191-200 of 211) with videos related to

Sort By:
Pageof 22
Oncogene|December 11, 2024
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcomaSatoshi Takagi, Mikako Nakajima, Sumie Koike, et al.
Scientific Reports|August 23, 2017
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcomaNaoya Maekawa, Satoru Konnai, Satoshi Takagi, et al.
Scientific Reports|June 6, 2022
Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapyNaoya Maekawa, Satoru Konnai, Yumie Asano, et al.
American Journal of Hematology|May 6, 2017
A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformationAntonio Sacco, Yawara Kawano, Michele Moschetta, et al.
Internal Medicine (Tokyo, Japan)|November 20, 2018
Community-acquired Disseminated Exophiala dermatitidis Mycosis with Necrotizing Fasciitis in Chronic Graft-versus-host DiseaseEiichi Sato, Atsushi Togawa, Michio Masaki, et al.
The Journal of Cell Biology|November 5, 2003
Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalitiesSatoru Yamazaki, Ryo Iwamoto, Kazuko Saeki, et al.
Cancers|June 10, 2023
Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant MelanomaTatsuya Deguchi, Naoya Maekawa, Satoru Konnai, et al.
NPJ Precision Oncology|February 13, 2021
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanomaNaoya Maekawa, Satoru Konnai, Maki Nishimura, et al.
JCI Insight|December 7, 2021
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylationRay Sagawa, Seiji Sakata, Bo Gong, et al.
Plos One|January 26, 2023
Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumorsNaoya Maekawa, Satoru Konnai, Yumie Asano, et al.
Pageof 22